Abstract:
BACKGROUND:The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemic. METHODS:Of 19 342 hypertensive patients (aged 40-79 years with at least three other cardiovascular risk factors) randomised to one of two antihypertensive regimens in the Anglo-Scandinavian Cardiac Outcomes Trial, 10,305 with nonfasting total cholesterol concentrations 6.5 mmol/L or less were randomly assigned additional atorvastatin 10 mg or placebo. These patients formed the lipid-lowering arm of the study. We planned follow-up for an average of 5 years, the primary endpoint being non-fatal myocardial infarction and fatal CHD. Data were analysed by intention to treat. FINDINGS:Treatment was stopped after a median follow-up of 3.3 years. By that time, 100 primary events had occurred in the atorvastatin group compared with 154 events in the placebo group (hazard ratio 0.64 [95% CI 0.50-0.83], p = 0.0005). This benefit emerged in the first year of follow-up. There was no significant heterogeneity among prespecified subgroups. Fatal and non-fatal stroke (89 atorvastatin vs 121 placebo, 0.73 [0.56-0.96], p = 0.024), total cardiovascular events (389 vs 486, 0.79 [0.69-0.90], p = 0.0005), and total coronary events (178 vs 247, 0.71 [0.59-0.86], p = 0.0005) were also significantly lowered. There were 185 deaths in the atorvastatin group and 212 in the placebo group (0.87 [0.71-1.06], p = 0.16). Atorvastatin lowered total serum cholesterol by about 1.3 mmol/L compared with placebo at 12 months, and by 1.1 mmol/L after 3 years of follow-up. INTERPRETATION:The reductions in major cardiovascular events with atorvastatin are large, given the short follow-up time. These findings may have implications for future lipid-lowering guidelines.
journal_name
Drugsjournal_title
Drugsauthors
Sever PS,Dahlöf B,Poulter NR,Wedel H,Beevers G,Caulfield M,Collins R,Kjeldsen SE,Kristinsson A,McInnes GT,Mehlsen J,Nieminen M,O'Brien E,Ostergren J,ASCOT Investigators.doi
10.2165/00003495-200464002-00005subject
Has Abstractpub_date
2004-01-01 00:00:00pages
43-60eissn
0012-6667issn
1179-1950journal_volume
64 Suppl 2pub_type
临床试验,杂志文章,多中心研究,随机对照试验相关文献
DRUGS文献大全abstract::The objective of surgical prophylaxis is to prevent wound infections associated with surgery. The rates of wound infections vary according to the procedure: less than 3 infections per 100 for clean procedures; up to 4 per 100 for clean-contaminated procedures; and up to 9 per 100 for contaminated procedures. Surgical ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199300453-00018
更新日期:1993-01-01 00:00:00
abstract::Because of inappropriate signals from the volume-regulation system and a reduction in renal blood flow, the kidney is not able to prevent sodium and water retention in chronic congestive heart failure (CHF). A brief summary of normal renal function and renal involvement in CHF is given and a study of renal function in...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-199000394-00004
更新日期:1990-01-01 00:00:00
abstract::Each antiarrhythmic agent can cause side effects, but most of these are easily recognised by the patient or physician. However, one potentially serious side effect common to all of these drugs is aggravation of ventricular arrhythmia. Often this is without symptoms and goes unrecognised by the patient. It occurs in 11...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198500294-00009
更新日期:1985-01-01 00:00:00
abstract::Cephalosporins have a role in the treatment of gonorrhoea, and especially infections caused by strains that are penicillin-resistant, either because they produce plasmid-mediated beta-lactamase or they have chromosomally mediated diminished permeability or modified penicillin-binding proteins. Although none of the ora...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198700342-00013
更新日期:1987-01-01 00:00:00
abstract::Entecavir (Baraclude) is a novel nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus (HBV). In large, randomised, double-blind, phase III clinical trials in patients with chronic HBV infection, oral entecavir 0.5 or 1.0mg once daily for up to 96 ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666120-00009
更新日期:2006-01-01 00:00:00
abstract::Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01417-6
更新日期:2020-11-01 00:00:00
abstract::Tipranavir (Aptivus) is a selective nonpeptidic HIV-1 protease inhibitor (PI) that is used in the treatment of treatment-experienced adults with HIV-1 infection. Tipranavir is administered orally twice daily and must be given in combination with low-dose ritonavir, which is used to boost its bioavailability. The durab...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868100-00006
更新日期:2008-01-01 00:00:00
abstract::Early identification of infants with sickle cell disease (SCD) by newborn screening, now universal in all 50 states in the US, has improved survival, mainly by preventing overwhelming sepsis with the early use of prophylactic penicillin. Routine transcranial Doppler screening with the institution of chronic transfusio...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11632890-000000000-00000
更新日期:2012-05-07 00:00:00
abstract::The emergence of antibiotic resistance is primarily due to excessive and often unnecessary use of antibiotics in humans and animals. Risk factors for the spread of resistant bacteria in hospitals and the community can be summarised as over-crowding, lapses in hygiene or poor infection control practices. Increasing ant...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199855030-00001
更新日期:1998-03-01 00:00:00
abstract::Pegylation of interferon-alpha-2a is associated with improved sustained virological response rates in patients with chronic hepatitis C. Subsequently, combination therapy with peginterferon-alpha-2a (40kD) [Pegasys] and ribavirin (Copegus trade mark, Rebetol) was investigated to establish if the efficacy of peginterfe...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200363070-00008
更新日期:2003-01-01 00:00:00
abstract::The optimal pharmacological therapy of community-acquired pneumonia (CAP) is one of the most ardently debated issues in medicine. Presently, most guidelines recommend either a fluoroquinolone alone or dual therapy with a third-generation cephalosporin plus a macrolide in patients hospitalised with CAP, but few provide...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200565140-00004
更新日期:2005-01-01 00:00:00
abstract::Viral respiratory tract infections (RTIs) are common causes of mild illness in immunocompetent children and adults, with occasional significant morbidity or mortality in the very young, very old or infirm. However, recipients of solid organ transplants (SOT) or haematopoietic stem cell transplants (HSCT) are at marked...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767100-00004
更新日期:2007-01-01 00:00:00
abstract::Olaratumab (Lartruvo™) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) receptor α (PDGFRα). It was developed by Eli Lilly and Co. (previously ImClone Systems) after PDGFRα was identified as a potential therapeutic target in a variety of cancers. Olaratumab act...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0680-2
更新日期:2017-01-01 00:00:00
abstract::Cefixime is an orally active third generation cephalosporin with in vitro antibacterial activity against most important lower respiratory pathogens. The drug is active against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae but not Staphylococcus aureus. Cefixime has a...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199549060-00010
更新日期:1995-06-01 00:00:00
abstract::Inhaled mometasone furoate (Asmanex) is a synthetic corticosteroid indicated for the first-line maintenance prophylactic therapy of persistent asthma in adults and adolescents. It is formulated for delivery via a breath-actuated dry powder inhaler (DPI) [Twisthaler].Inhaled mometasone furoate delivered by DPI is effec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666080-00011
更新日期:2006-01-01 00:00:00
abstract::Exenatide extended-release (exenatide ER) [Bydureon(®)] is a glucagon-like peptide-1 receptor agonist, approved for the treatment of type 2 diabetes mellitus. It is injected subcutaneously by patients once weekly, with no dose titration required. This article updates an earlier review of exenatide ER in the management...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0420-z
更新日期:2015-07-01 00:00:00
abstract::Arrhythmia treatment has always been difficult, particularly as there are no good indicators of the optimal management strategy. The introduction of new antiarrhythmic agents has forced reappraisal of how these drugs are used. Dynamic electrocardiography and invasive electrophysiological studies are important tools fo...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198836050-00005
更新日期:1988-11-01 00:00:00
abstract::Diuretics are used in first-step antihypertensive monotherapy or in combination with adrenergic-inhibiting agents in the majority of hypertensive patients in the United States. A 30-year experience has demonstrated that blood pressure is lowered to as great or greater a degree with diuretics than when many of the pres...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198600314-00007
更新日期:1986-01-01 00:00:00
abstract::Approximately 70% of invasive breast cancers have some degree of dependence on the estrogen hormone for cell proliferation and growth. These tumors have estrogen and/or progesterone receptors (ER/PR+), generally referred to as hormone receptor positive (HR+) tumors, as indicated by the presence of positive staining an...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01394-w
更新日期:2020-11-01 00:00:00
abstract::Pomalidomide (Imnovid®; Pomalyst®), an analogue of thalidomide, is an immunomodulatory agent, with several mechanisms of action (both direct and indirect) thought to be involved in its anti-myeloma activity. Oral pomalidomide is available in several countries for use in combination with low-dose dexamethasone in adult...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0833-y
更新日期:2017-11-01 00:00:00
abstract::The original article has been corrected. ...
journal_title:Drugs
pub_type: 杂志文章,已发布勘误
doi:10.1007/s40265-020-01280-5
更新日期:2020-03-01 00:00:00
abstract::Cisatracurium besilate (besylate) is a nondepolarising neuromuscular blocking agent with an intermediate duration of action. It is the R-cis, R'-cis isomer of atracurium besilate and is approximately 3-fold more potent than the mixture of isomers that constitute the parent drug. The ED95 for cisatracurium besilate (do...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199753050-00012
更新日期:1997-05-01 00:00:00
abstract::Acamprosate (Campral(®), Aotal(®), Regtect(®)) is one of a limited number of pharmacological treatment options approved as an adjunct to psychosocial interventions to facilitate the maintenance of abstinence in alcohol-dependent patients. It has been used in Europe, the USA and other countries for many years and was r...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0423-9
更新日期:2015-07-01 00:00:00
abstract::Antiviral therapy has in the past met with limited success and only a few antiviral drugs have been available. The human immunodeficiency virus (HIV) epidemic has created an urgent need for the development of antiviral therapy against this infection. HIV replication offers several targets for inhibitory compounds, the...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199345040-00002
更新日期:1993-04-01 00:00:00
abstract::Acute myocardial infarction (AMI) recognises no boundaries, and the patient's greatest need occurs at the interface between primary care and hospital system. Ideally, the general practitioner, if summoned, should be able to provide resuscitation, analgesia with opiates, and thrombolytic therapy. Thrombolytics should c...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199550040-00004
更新日期:1995-10-01 00:00:00
abstract::Osteoarthritis, the most common rheumatic disease, presents the clinician with a major therapeutic and management task. The chronic and progressive course of the disease is punctuated by pain, declining function and escalating disability. This article attempts to deal with the pharmacological therapeutic options avail...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199141020-00005
更新日期:1991-02-01 00:00:00
abstract::The increased understanding of the mechanisms which underlie rheumatoid disease has been accompanied by a more appropriate use of the limited repertoire of therapeutic agents. Conventional second-line drugs still have a role in everyday practice. The efficacy of these agents in reducing the severity of clinical signs ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199447020-00003
更新日期:1994-02-01 00:00:00
abstract::Aspirin (acetylsalicylic acid)-induced asthma (AIA) consists of the clinical triad of asthma, chronic rhinosinusitis with nasal polyps, and precipitation of asthma and rhinitis attacks in response to aspirin and other NSAIDs. The prevalence of the syndrome in the adult asthmatic populations is approximately 4-10%. Res...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200464210-00004
更新日期:2004-01-01 00:00:00
abstract::The cardiovascular and cardiorenal disease continuum comprises the transition from cardiovascular risk factors to endothelial dysfunction and atherosclerosis, to clinical complications such as myocardial infarction (MI) and stroke, to the development of persistent target-organ damage and, ultimately, to chronic conges...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11537910-000000000-00000
更新日期:2010-07-09 00:00:00
abstract::A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0558-3
更新日期:2016-04-01 00:00:00